A detailed history of Fayez Sarofim & CO transactions in Novo Nordisk A S stock. As of the latest transaction made, Fayez Sarofim & CO holds 12,217,118 shares of NVO stock, worth $1.07 Billion. This represents 3.76% of its overall portfolio holdings.

Number of Shares
12,217,118
Previous 12,552,088 2.67%
Holding current value
$1.07 Billion
Previous $1.79 Billion 18.81%
% of portfolio
3.76%
Previous 4.91%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$119.07 - $145.42 $39.9 Million - $48.7 Million
-334,970 Reduced 2.67%
12,217,118 $1.45 Billion
Q2 2024

Aug 14, 2024

BUY
$122.71 - $146.91 $90.3 Million - $108 Million
736,251 Added 6.23%
12,552,088 $1.79 Billion
Q1 2024

May 14, 2024

BUY
$102.11 - $135.92 $182,368 - $242,753
1,786 Added 0.02%
11,815,837 $1.52 Billion
Q4 2023

Feb 14, 2024

BUY
$87.78 - $105.45 $18.4 Million - $22.2 Million
210,087 Added 1.81%
11,814,051 $1.22 Billion
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $590 Million - $1.29 Billion
6,484,279 Added 126.65%
11,603,964 $1.06 Billion
Q2 2023

Aug 14, 2023

SELL
$155.98 - $172.65 $25.1 Million - $27.7 Million
-160,672 Reduced 3.04%
5,119,685 $829 Million
Q1 2023

May 11, 2023

BUY
$132.34 - $159.14 $21.7 Million - $26.1 Million
163,988 Added 3.21%
5,280,357 $840 Million
Q4 2022

Feb 13, 2023

SELL
$102.55 - $135.33 $10.4 Million - $13.8 Million
-101,735 Reduced 1.95%
5,116,369 $692 Million
Q3 2022

Nov 14, 2022

BUY
$95.28 - $116.93 $42.9 Million - $52.7 Million
450,280 Added 9.44%
5,218,104 $520 Million
Q2 2022

Aug 12, 2022

BUY
$103.24 - $121.81 $68,241 - $80,516
661 Added 0.01%
4,767,824 $531 Million
Q1 2022

May 16, 2022

SELL
$93.1 - $112.54 $6.05 Million - $7.32 Million
-65,017 Reduced 1.35%
4,767,163 $529 Million
Q4 2021

Feb 11, 2022

SELL
$95.88 - $117.08 $8.64 Million - $10.5 Million
-90,094 Reduced 1.83%
4,832,180 $541 Million
Q3 2021

Nov 15, 2021

SELL
$84.42 - $106.62 $724,998 - $915,652
-8,588 Reduced 0.17%
4,922,274 $473 Million
Q2 2021

Aug 13, 2021

SELL
$67.66 - $84.76 $2.33 Million - $2.92 Million
-34,493 Reduced 0.69%
4,930,862 $413 Million
Q1 2021

May 13, 2021

SELL
$67.06 - $75.82 $1.21 Million - $1.37 Million
-18,092 Reduced 0.36%
4,965,355 $335 Million
Q4 2020

Feb 11, 2021

SELL
$63.89 - $73.8 $1.07 Million - $1.23 Million
-16,730 Reduced 0.33%
4,983,447 $348 Million
Q3 2020

Nov 13, 2020

SELL
$63.69 - $70.22 $4 Million - $4.41 Million
-62,870 Reduced 1.24%
5,000,177 $347 Million
Q2 2020

Aug 11, 2020

BUY
$58.54 - $67.94 $49.1 Million - $56.9 Million
838,111 Added 19.84%
5,063,047 $332 Million
Q1 2020

May 12, 2020

SELL
$49.46 - $64.78 $8.89 Million - $11.6 Million
-179,664 Reduced 4.08%
4,224,936 $254 Million
Q4 2019

Feb 14, 2020

SELL
$49.86 - $58.26 $5.75 Million - $6.71 Million
-115,224 Reduced 2.55%
4,404,600 $255 Million
Q3 2019

Nov 13, 2019

BUY
$47.54 - $53.43 $1.66 Million - $1.86 Million
34,846 Added 0.78%
4,519,824 $234 Million
Q2 2019

Aug 09, 2019

BUY
$46.79 - $52.47 $642,239 - $720,203
13,726 Added 0.31%
4,484,978 $229 Million
Q1 2019

May 14, 2019

BUY
$46.36 - $52.63 $507,271 - $575,877
10,942 Added 0.25%
4,471,252 $234 Million
Q4 2018

Feb 13, 2019

BUY
$41.54 - $47.25 $81,626 - $92,846
1,965 Added 0.04%
4,460,310 $205 Million
Q3 2018

Nov 14, 2018

SELL
$46.76 - $51.24 $1.81 Million - $1.98 Million
-38,615 Reduced 0.86%
4,458,345 $210 Million
Q2 2018

Aug 14, 2018

SELL
$44.29 - $50.42 $6.4 Million - $7.29 Million
-144,498 Reduced 3.11%
4,496,960 $207 Million
Q1 2018

May 10, 2018

SELL
$48.49 - $58.14 $4.6 Million - $5.52 Million
-94,944 Reduced 2.0%
4,641,458 $229 Million
Q4 2017

Feb 13, 2018

SELL
$47.53 - $53.73 $14.1 Million - $16 Million
-297,677 Reduced 5.91%
4,736,402 $254 Million
Q3 2017

Nov 08, 2017

BUY
$41.15 - $49.22 $207 Million - $248 Million
5,034,079
5,034,079 $242 Million

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $197B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Fayez Sarofim & CO Portfolio

Follow Fayez Sarofim & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.